Anti-allergic drug azelastine suppresses colon tumorigenesis by directly targeting ARF1 to inhibit IQGAP1-ERK-Drp1-mediated mitochondrial fission
Huifang Hu, Wen Xu, Yang‐Jia Li, Yan He, Wei‐Xia Zhang, Long Liao, Qihua Zhang, Lei Han, Xingfeng Yin, Zhao Xiao-xu, Yun-long Pan, Bin Li, Qing‐Yu He
Abstract
This study provides the first evidence that azelastine may be novel therapeutics for CRC treatment. ARF1 promotes colon tumorigenesis, representing a promising biomarker and therapeutic target in CRC.
Topics & Concepts
Mitochondrial fissionAzelastineMAPK/ERK pathwayIQGAP1ChemistryCarcinogenesisMitochondrionCell biologyKinasePharmacologyMedicineBiologySignal transductionScaffold proteinBiochemistryGeneReceptor Mechanisms and SignalingHormonal Regulation and HypertensionProtein Kinase Regulation and GTPase Signaling